Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...
An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...